



IPO NOTE

INVENTURUS KNOWLEDGE SOLUTIONS LIMITED

Rating:

SUBSCRIBE

(For long term)



ISSUE OFFER

| | |
|----------------------------|--------------|
| Issue Opens on | DEC 12, 2024 |
| Issue Close on | DEC 16, 2024 |
| Total IPO size (cr) | ₹2,497.92 |
| Fresh issue (cr) | NIL |
| Offer For Sale (cr) | ₹2,497.92 |
| Price Band (INR) | 1265 - 1329 |
| Market Lot | 11 |
| Face Value (INR) | ₹1 |
| Listing At | NSE, BSE |
| Market Capitalization (cr) | 22802.07 |

ISSUE BREAK-UP (%)

| | | |
|----------------|---------------------------------|-----|
| QIB Portion | <div style="width: 75%;"></div> | 75% |
| NII Portion | <div style="width: 10%;"></div> | 10% |
| Retail Portion | <div style="width: 15%;"></div> | 15% |

INDICATIVE TIMETABLE

| | |
|------------------------------|------------|
| Basis of Allotment | 17-12-2024 |
| Refunds/Unblocking ASBA Fund | 18-12-2024 |
| Credit of Share to Demat A/c | 19-12-2024 |
| Listing Date | 19-12-2024 |

Inventurus Knowledge Solutions Limited (IKS Health) provides services to healthcare enterprises such as handling administrative chores/work. The company helps doctors and other healthcare providers by handling their paperwork and administrative tasks.

OBJECTS OF THE ISSUE

- The issue is complete offer for sale.

FINANCIALS (RESTATED CONSOLIDATED)

| PARTICULARS (IN CRORE) | FY 2024 | FY 2023 | FY 2022 |
|---------------------------|----------|----------|---------|
| Equity Share Capital | 16.92 | 16.84 | 16.81 |
| Net Worth | 1,157.86 | 828.64 | 647.07 |
| RONW% | 32.00% | 36.83% | 36.00% |
| Revenue | 1,817.93 | 1,031.30 | 763.63 |
| Operating Profit Margin % | 30.78% | 37.94% | 38.92% |
| Net Profit of the year | 370.49 | 305.23 | 232.97 |

FINANCIAL RATIOS OF FY24



OUTLOOK & VALUATION

- Leading partner for outpatient and inpatient care organizations.
- Healthy financial performance with growth and improving margins
- No listed peers.
- Complete OFS: The Company receives no proceeds from the IPO.
- Investment recommendation: Suitable for long term investors.



COMPANY PROFILE

- IKS Health offers services such as clinical support, medical documentation management, virtual medical scribing and more.
- Inventurus Knowledge Solutions Limited offer a platform that enables healthcare enterprises in outpatient and inpatient care.
- The company is a healthcare technology company that helps make it easier and faster for patients to get the care they need while reducing the administrative burden on healthcare providers.



COMPETITIVE STRATEGIES

- Maximise revenue from existing clients through a “land and expand” approach.
- Move from a “human-led tech-enabled” model to a “tech-led human-enabled” model.
- Partner with innovative clients for product development and innovation.
- Bundling the solutions for greater value-add.
- Leverage automation and Generative Artificial Intelligence (AI) to aid the operations.



KEY CONCERNS

- The healthcare industry is regulated.
- Various challenges currently faced by the healthcare industry in the United States.
- Revenues are dependent on the ability to maintain and expand existing client relationships.
- Revenues are primarily dependent on revenue generated from healthcare organizations based in the United State.



KEY STRENGTHS

- Healthy financial performance.
- Experienced and entrepreneurial driven leadership team.
- Strong brand driven by clinical thought leadership through IKS Advisory Board.
- Sustainable and scalable business model offering clients flexibility and cost-savings.

COMPARISON WITH LISTED INDUSTRY PEERS

- THERE ARE NO LISTED COMPANIES IN INDIA WHOSE BUSINESS PORTFOLIO IS COMPARABLE WITH THAT OF THE BUSINESS AND COMPARABLE TO THE SCALE OF OPERATIONS. HENCE, IT IS NOT POSSIBLE TO PROVIDE AN INDUSTRY COMPARISON IN RELATION TO THE COMPANY.



DISCLAIMER:

The information contained herein are strictly confidential and are meant solely for the information of the recipient and shall not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written permission of Swastika Investmart Ltd. ("SIL"). The contents of this document are for information purpose only. This document is not an investment advice and must not alone be taken as the basis for an investment decision. Before taking any decision to invest, the recipient of this document must read carefully the Red Herring Prospectus ("RHP") issued to know the details of IPO and various risks and uncertainties associated with the investment in the IPO of the Company. All recipients of this document must before acting on the given information/details, make their own investigation and apply independent judgment based on their specific investment objectives and financial position. They can also seek appropriate professional advice from their own legal and tax consultants, advisors, etc. to understand the risks and investment considerations arising from such investment. The investor should possess appropriate resources to analyze such investment and the suitability of such investment to such investor's particular circumstances before making any decisions on the investment. The Investor shall be solely responsible for any action taken based on this document. SIL shall not be liable for any direct or indirect losses arising from the use of the information contained in this document and accept no responsibility for statements made otherwise issued or any other source of information received by the investor and the investor would be doing so at his/her/its own risk. The information contained in this document should not be construed as forecast or promise or guarantee or assurance of any kind. The investors are not being offered any assurance or guaranteed or fixed returns on their investments. The users of this document must bear in mind that past performances if any, are not indicative of future results. The actual returns on investment may be materially different than the past. Investments in Securities market products and instruments including in the IPO of the Company are highly risky and they are generally not an appropriate avenue for someone with limited resources/ limited investment and low risk tolerance. Such Investments are subject to market risks including, without limitation, price, volatility and liquidity and capital risks. Therefore, the users of this document must carefully consider all the information given in the RHP including the risks factors before making any investment in the Equity Shares of the Company.

Swastika Investmart Ltd or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Swastika Investmart Ltd nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Swastika Investment Ltd may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the Subject Company or third party in connection with the Research Report.

CORPORATE & ADMINISTRATIVE OFFICE - 48, Jaora Compound, M.Y.H. Road, Indore - 452 001 | Phone 0731 - 6644000

Compliance Officer: Ms. Sheetal Duraphe Email: compliance@swastika.co.in Phone: (0731) 6644 241

Swastika Investmart Limited, SEBI Reg. No. : NSE/BSE/MSEI: INZ000192732 Merchant Banking: INM000012102 Investment Adviser: INA000009843 MCX/NCDEX: INZ000072532

CDSL/NSDL: IN-DP-115-2015 RBI Reg. No.: B-03-00174 IRDA Reg. No.: 713.